Bayer Challenges J&J OTC Leadership With Buy Of China's Dihon Pharma
This article was originally published in PharmAsia News
Bayer plans to buy Dihon Pharmaceutical Group, a China-based maker of traditional Chinese medicine, in a push to challenge Johnson & Johnson's leadership in the global over-the-counter market.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.